248 related articles for article (PubMed ID: 28970176)
1. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
3. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
[TBL] [Abstract][Full Text] [Related]
4. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Scott BL; Gooley TA; Sorror ML; Rezvani AR; Linenberger ML; Grim J; Sandmaier BM; Myerson D; Chauncey TR; Storb R; Buxhofer-Ausch V; Radich JP; Appelbaum FR; Deeg HJ
Blood; 2012 Mar; 119(11):2657-64. PubMed ID: 22234678
[TBL] [Abstract][Full Text] [Related]
5. Survival following allogeneic transplant in patients with myelofibrosis.
Gowin K; Ballen K; Ahn KW; Hu ZH; Ali H; Arcasoy MO; Devlin R; Coakley M; Gerds AT; Green M; Gupta V; Hobbs G; Jain T; Kandarpa M; Komrokji R; Kuykendall AT; Luber K; Masarova L; Michaelis LC; Patches S; Pariser AC; Rampal R; Stein B; Talpaz M; Verstovsek S; Wadleigh M; Agrawal V; Aljurf M; Angel Diaz M; Avalos BR; Bacher U; Bashey A; Beitinjaneh AM; Cerny J; Chhabra S; Copelan E; Cutler CS; DeFilipp Z; Gadalla SM; Ganguly S; Grunwald MR; Hashmi SK; Kharfan-Dabaja MA; Kindwall-Keller T; Kröger N; Lazarus HM; Liesveld JL; Litzow MR; Marks DI; Nathan S; Nishihori T; Olsson RF; Pawarode A; Rowe JM; Savani BN; Savoie ML; Seo S; Solh M; Tamari R; Verdonck LF; Yared JA; Alyea E; Popat U; Sobecks R; Scott BL; Nakamura R; Mesa R; Saber W
Blood Adv; 2020 May; 4(9):1965-1973. PubMed ID: 32384540
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk models for transplant decision-making in myelofibrosis.
Hernández-Boluda JC; Pereira A; Correa JG; Alvarez-Larrán A; Ferrer-Marín F; Raya JM; Martínez-López J; Velez P; Pérez-Encinas M; Estrada N; García-Gutiérrez V; Fox ML; Payer A; Kerguelen A; Cuevas B; Durán MA; Ramírez MJ; Gómez-Casares MT; Mata-Vázquez MI; Mora E; Gómez M; Cervantes F
Ann Hematol; 2018 May; 97(5):813-820. PubMed ID: 29396714
[TBL] [Abstract][Full Text] [Related]
7. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
[TBL] [Abstract][Full Text] [Related]
8. Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation.
Stevens EA; Jenkins IC; Beppu LW; Zhang Q; Salit R; Loeb KR; Deeg HJ; Radich JP
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1371-1374. PubMed ID: 32194289
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.
Tefferi A; Partain DK; Palmer JM; Slack JL; Roy V; Hogan WJ; Litzow ML; Ketterling RP; Patnaik MM
Am J Hematol; 2018 May; 93(5):649-654. PubMed ID: 29388258
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Sheth AH; Vetsa S; Grimshaw A; Giri S; Podoltsev NA; Gowda L; Tamari R; Tallman MS; Rampal RK; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Oct; 27(10):873.e1-873.e13. PubMed ID: 34052505
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
[TBL] [Abstract][Full Text] [Related]
14. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.
Gupta V; Malone AK; Hari PN; Ahn KW; Hu ZH; Gale RP; Ballen KK; Hamadani M; Olavarria E; Gerds AT; Waller EK; Costa LJ; Antin JH; Kamble RT; van Besien KM; Savani BN; Schouten HC; Szer J; Cahn JY; de Lima MJ; Wirk B; Aljurf MD; Popat U; Bejanyan N; Litzow MR; Norkin M; Lewis ID; Hale GA; Woolfrey AE; Miller AM; Ustun C; Jagasia MH; Lill M; Maziarz RT; Cortes J; Kalaycio ME; Saber W
Biol Blood Marrow Transplant; 2014 Jan; 20(1):89-97. PubMed ID: 24161923
[TBL] [Abstract][Full Text] [Related]
16. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
[TBL] [Abstract][Full Text] [Related]
18. [A study of prognostic value of cytogenetics in patients with primary myelofibrosis].
Li B; Xu J; Xu Z; Li C; Qin T; Fang L; Zhang H; Hu N; Pan L; Qu S; Wang J; Zhang Y; Zhang P; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):990-4. PubMed ID: 25417875
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
[TBL] [Abstract][Full Text] [Related]
20. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Horvat NP; Abdallah EF; Xie Z; Al Ali N; Yun S; Walker A; Padron E; Sallman D; Chan O; Lancet J; Komrokji R; Kuykendall AT
Ann Hematol; 2024 Jan; 103(1):117-123. PubMed ID: 38030891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
